<DOC>
	<DOCNO>NCT00572299</DOCNO>
	<brief_summary>The purpose study determine difference response bisphosphonate therapy patient receive excess glucocorticoid compare patient postmenopausal male osteoporosis . Bisphosphonates approved FDA treatment postmenopausal woman osteoporotic men high risk fracture men woman excess glucocorticoid administration .</brief_summary>
	<brief_title>Glucocorticoids Promote Osteoclast Survival</brief_title>
	<detailed_description>Aminobisphosphonates extensively use prevent fracture patient osteoporosis ( 1-6 ) . Treatment drug lead decrease bone resorption biochemical marker bone turnover progressive increase bone mineral density ( BMD ) . The increase BMD response bisphosphonate therapy glucocorticoid-treated patient , however , less half measure woman men osteoporosis unrelated glucocorticoid drug even though patient osteoporosis usually old . The goal objective determine contribution increase osteoclast survival diminish response bisphosphonate therapy patient receive excess glucocorticoid compare patient osteoporosis . 1 . Liberman U , Weiss SR , Broll J , et al . Effect oral alendronate bone mineral density incidence fracture postmenopausal osteoporosis . N Engl J Med 1995 ; 333:1437-1443 . 2 . Bone HG , Downs RW , Tucci JR , et al . Dose-response relationship alendronate treatment osteoporotic elderly woman . J Clin Endocrinol Metab 1997 ; 82:265-274 . 3 . McClung M , Clemmesen B , Daifotis A , et al . Alendronate prevents postmenopausal bone loss woman without osteoporosis . Ann Intern Med 1998 ; 128:253-261 . 4 . Recker RR , Weinstein RS , Chestnut CH III , et al . Histomorphometric evaluation daily intermittent oral ibandronate woman postmenopausal osteoporosis : result BONE study . Osteoporosis Int 2004 ; 15:231-237 . 5 . Saag KG , Emkey R , Schnitzer TJ , et al . Alendronate prevention treatment glucocorticoid-induced osteoporosis . Glucocorticoid-Induced Osteoporosis Intervention Study Group . N Engl J Med 1998 ; 339:292-299 . 6 . Orwoll E , Ettinger M , Weiss S , et al . Alendronate treatment osteoporosis men . N Engl J Med 2000 ; 343:604-610 .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>1 . 18 year old great 2. agree least one bone biopsy 3. agree BMD , blood urine test 4. receive least 10 mg/day prednisone least three month 5. either candidate alendronate take alendronate ( 70 mg/week least three month ) 1. metabolic bone disorder Paget 's disease , renal osteodystrophy , parathyroid disease osteomalacia 2. obesity enough make biopsy difficult 3. concurrent use tetracycline 4. hypercalcemia 5. kidney stone last two year 6. home O2 7. gastric surgery , staple bypass 8. inflammatory bowel disease 9. untreated thyroid disease 10. organ transplant 11. malabsorption 12. anticoagulation 13. current infection 14. serious illness 15. allergy Demerol , Valium , iodine , tetracycline , tape 16. use anticonvulsant drug , heparin , Forteo , calcitonin highdose fluoride within past six month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>glucocorticoid , prednisone , alendronate , osteoclast</keyword>
</DOC>